The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOCUS-HSBC loses senior European deal-makers as M&A ranking drops - sources

Thu, 31st May 2018 18:51

* More than 10 bankers quit in last 6 months - sources

* HSBC ranking in global M&A advisory list slips to 42

* Bankers complain of lack of leadership, strategy - sources

* Spokesman says new hires globally outweigh EU departures

By Pamela Barbaglia

LONDON, May 31 (Reuters) - At least 10 high-profiledealmakers in Europe have left HSBC in recent months ata time of record merger activity, after the bank failed tooverhaul its investment banking unit and revamp client teams,four sources said.

Overall dozens of investment bankers have quit, includingsenior managers at the bank's top performing European privateequity team, the sources familiar with the matter told Reuters.

The departures reflect a growing sense of frustration overwhat the sources said was a lack of clear investment bankingstrategy at Europe's biggest bank and its failure to rebuild acompetitive team on the continent.

They also highlight the difficulties European banks face incatching up with Wall Street rivals, whose dominance ininvestment banking league tables has increased.

A spokesman for HSBC said the bank hired dozens of seniorbankers recently, significantly outweighing the number ofdepartures. The majority of the hires are based in North Americaand Asia, according to a list provided by the bank.

"We continue to see good momentum across our financing andadvisory franchise, taking leading roles in recent high-profiletransactions," the spokesman said.

Chief Executive John Flint said in April that he wanted todouble down on HSBC's "pivot" to Asia and China in particular.On Feb. 27, the bank announced two hires in North America tostrengthen its investment banking there.

Flint will unveil his strategy on June 11 and is expected toannounce further investment in China.

While there is no hiring spree, the bank is seeking to scaleup its presence outside Europe.

Some staff told Reuters they left because they felt theEuropean business was rudderless.

One of HSBC's most senior dealmakers in Germany, NorbertReis, will leave in June, according to the sources. Hepreviously served as head of global banking in Germany.

HSBC's consumer and retail director Patrick Philion andEuropean private equity co-head Umberto Giacometti both quit inMay to join Nomura, the sources added.

The departures follow the abrupt exit in November of HSBC'stop investment banker, Matthew Westerman, a Goldman Sachsveteran hired with a mandate to shake up the investment bankingunit in Europe and revive growth.

"BARE BONES"

Like most global banks, HSBC had been shrinking itsinvestment banking business following the financial crisis. In2015 it slashed nearly 50,000 jobs and cut its investment bankby a third to restore growth across its sprawling empire.

Westerman's appointment in 2016 was aimed at regainingmarket share and competing with U.S. rivals. Instead, he leftafter 18 months, having cut 100 jobs, and has not been replaced.

"Westerman did the clean-up job but had no time to rebuildand reorganise the unit," said one banker who left recently."Most teams have been reduced to the bare bones."

Other bankers also said HSBC had lost direction sinceWesterman's departure and questioned the depth of its commitmentto growing its investment banking franchise.

The turnover appears to have taken its toll, with HSBCdropping to 42nd this year in the global M&A advisory rankingfrom 15th a year ago, according to Thomson Reuters data.

M&A advisory has never been a strong area for HSBC, which ismostly known for its debt capital markets and lending activity.But over the past five years its M&A ranking ranged between 17thand 24th.

DEFECTIONS

The bank's private equity and leveraged finance teams havebeen hit hard by recent defections.

HSBC global private equity head Alexis Maskell left in Marchto join Citi while Bala Ramesh, a director in leveraged creditsyndicate, quit in October to join Jefferies.

Maskell's right-hand man Giacometti left in mid-May after 11years at the bank while Tim Kerry, a managing directorspecialising in leveraged finance, resigned to join Barclays.

Omar Faruqui, previously co-head of European private equity,also joined Barclays in January.

Dan Cohen, the head of HSBC's high-yield trading, left thebank in April to join Nomura while Stephen Smith joined Barclayslast year as a director in the high-yield syndicate team.

Senior managing director Luca Pietrantoni was among the mostrecent departures.

A number of more junior bankers also moved on in recentweeks, including two associates in the financial sponsors team-- Gerald Aichberger and Carol Rusin -- and analyst EmielKhakhar.

Some industry sectors as well as regional teams in Europehave been left unstaffed, the sources said.

HSBC recently advised JAB Holdings on its 1.5 billion poundpurchase of UK food chain Pret A Manger and worked with Duluxpaint maker Akzo Nobel on its 10.1 billion euro sale of itsspecialty chemicals unit in March.

But the bank missed out on major roles in some of thebiggest deals this year, including Japanese firm Takeda's 45.3billion pound purchase of London-listed drugmaker Shire.

In a bid to win more M&A work, HSBC is in the process ofhiring former Morgan Stanley banker Kamal Jabre, who used to runthe Middle East and North African region, as its global head ofadvisory, a source close to the bank said.

HSBC declined to comment on the appointment. It recentlynamed one of its senior bankers, Borja Azpilicueta, as globalhead of financial sponsors, sovereign wealth funds andinstitutional private clients.

(Additional reporting by Lawrence White; Editing by MikeCollett-White)

More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.